Contributions
Abstract: 252
Type: Oral
Abstract Category: Clinical aspects of MS - 1 Diagnosis and differential diagnosis
Background: Myelin oligodendrocyte glycoprotein (MOG) antibody disease has recently emerged as a new inflammatory demyelinating disease of the CNS. Reports of the clinical phenotypes and outcomes vary according to cohort referral patterns.
Objective: Here we report the features from a large UK cohort identified through a single national laboratory.
Methods: 252 UK patients positive for serum MOG-Abs as tested by the Autoimmune Neurology Group in Oxford were analysed in terms of demographics and clinical presentation. From this cohort further clinical details were available from 75 patients seen in the nationally commissioned Oxford Neuromyelitis Optica service including a subset of 44 patients diagnosed and followed from disease onset.
Results: In total 57% were female and there was no ethnic bias. Isolated optic neuritis (55%, bilateral in almost a half) was the most common onset presentation followed by transverse myelitis and acute disseminated encephalomyelitis-like presentations (both 18%). Within the Oxford cohort 47% developed some form of disability at follow up (median 28 months): 16% of patients had visual acuity ≤ 6/36 in the worse eye, 7% had limited walking distance, permanent bladder dysfunction occurred in 28% patients (71% of these had additional bowel dysfunction) and erectile problems were present in 21% of males. Transverse myelitis at onset was the only significant predictor of permanent disability as a whole. In the cohort diagnosed after the onset attack 36% relapsed after median disease duration of 16 months and the annualized relapse rate was 0.2. The risk of relapse was significantly lower in patients who were treated for more than 3 months of prednisolone.
Conclusion: The risk of relapsing course is moderate in MOG-Ab disease and might be reduced by medium-term immunosuppression initiated at disease onset. Permanent disability if occurs more often involves sphincter and erectile functions than vision or mobility.
Disclosure: Authors have nothing to disclose.
Abstract: 252
Type: Oral
Abstract Category: Clinical aspects of MS - 1 Diagnosis and differential diagnosis
Background: Myelin oligodendrocyte glycoprotein (MOG) antibody disease has recently emerged as a new inflammatory demyelinating disease of the CNS. Reports of the clinical phenotypes and outcomes vary according to cohort referral patterns.
Objective: Here we report the features from a large UK cohort identified through a single national laboratory.
Methods: 252 UK patients positive for serum MOG-Abs as tested by the Autoimmune Neurology Group in Oxford were analysed in terms of demographics and clinical presentation. From this cohort further clinical details were available from 75 patients seen in the nationally commissioned Oxford Neuromyelitis Optica service including a subset of 44 patients diagnosed and followed from disease onset.
Results: In total 57% were female and there was no ethnic bias. Isolated optic neuritis (55%, bilateral in almost a half) was the most common onset presentation followed by transverse myelitis and acute disseminated encephalomyelitis-like presentations (both 18%). Within the Oxford cohort 47% developed some form of disability at follow up (median 28 months): 16% of patients had visual acuity ≤ 6/36 in the worse eye, 7% had limited walking distance, permanent bladder dysfunction occurred in 28% patients (71% of these had additional bowel dysfunction) and erectile problems were present in 21% of males. Transverse myelitis at onset was the only significant predictor of permanent disability as a whole. In the cohort diagnosed after the onset attack 36% relapsed after median disease duration of 16 months and the annualized relapse rate was 0.2. The risk of relapse was significantly lower in patients who were treated for more than 3 months of prednisolone.
Conclusion: The risk of relapsing course is moderate in MOG-Ab disease and might be reduced by medium-term immunosuppression initiated at disease onset. Permanent disability if occurs more often involves sphincter and erectile functions than vision or mobility.
Disclosure: Authors have nothing to disclose.